JP Morgan Chase
SNOA icon

JP Morgan Chase’s Sonoma Pharmaceuticals SNOA Stock Holding History

JP Morgan Chase’s Portfolio SNOA Stock Details SNOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-123
Closed -$255 – 8051
2026
Q1 		$255 Buy
123
+2
+2% +$6 ﹤0.01% 7234
2025
Q4 		$440 Sell
121
-2
-2% -$7 ﹤0.01% 7090
2025
Q3 		$477 Buy
123
+3
+3% +$12 ﹤0.01% 7056
2025
Q2 		$344 Sell
120
-18
-13% -$54 ﹤0.01% 6737
2025
Q1 		$302 Hold
138
– – ﹤0.01% 6752
2024
Q4 		$371 Hold
138
– – ﹤0.01% 6836
2024
Q3 		$424 Buy
+138
New +$704 ﹤0.01% 6819
2024
Q1 		– Sell
-1,652
Closed -$5.96K – 7850
2023
Q4 		$5.96K Buy
+1,652
New +$10.5K ﹤0.01% 6527
2023
Q2 		– Sell
-34
Closed -$1K – 7298
2023
Q1 		$1K Buy
+34
New +$876 ﹤0.01% 6550
2017
Q3 		– Sell
-2
Closed -$2K – 5162
2017
Q2 		$2K Buy
+2
New +$2.47K ﹤0.01% 4855

Other funds holding SNOA

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.94B AUM 20.7% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
GRP
Global Retirement Partners San Rafael, California $6.54B AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase's SNOA Position: Q2 2026 in Review

JP Morgan Chase sold out of Sonoma Pharmaceuticals (SNOA) in Q2 2026, closing a stake of 123 shares — an estimated $255 sold.

JP Morgan Chase first reported a position in SNOA in Q2 2017 and held it in 10 quarters. The position peaked at $5.96K in Q4 2023. 14 funds tracked by Wall St. Rank hold SNOA as of Q2 2026.

  • JP Morgan Chase reported no remaining Sonoma Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • JP Morgan Chase sold 123 Sonoma Pharmaceuticals shares in Q2 2026, an estimated $255.
  • JP Morgan Chase first reported a position in Sonoma Pharmaceuticals in Q2 2017 and held it in 10 quarters.
  • JP Morgan Chase's Sonoma Pharmaceuticals position peaked at $5.96K in Q4 2023.
  • 14 funds tracked by Wall St. Rank held Sonoma Pharmaceuticals as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.